The GoodRx Prescription Savings Blog

The latest updates on prescription drugs and ways to save from the GoodRx medical team

FDA Issues Safety Alert for Ocaliva

by The GoodRx Pharmacist on October 5, 2017 at 12:49 pm

On September 21st, the FDA issued a drug safety communication for Ocaliva (obeticholic acid), a medication used to treat primary biliary cholangitis (PBC).

The FDA warns that using Ocaliva can cause serious liver injury and even death when improperly dosed. The FDA has reviewed the 19 cases of death potentially caused by Ocaliva, and determined that in several cases patients with moderate to severe liver disease were receiving too high of a dose. This can result in an increased risk of serious liver injury or death.

What is Ocaliva indicated for?

Ocaliva is indicated in adults for the treatment of primary biliary cholangitis (PBC) with or without ursodeoxycholic acid.

Primary biliary cholangitis (PBC) is a rare liver disease in which your body begins to attack itself and destroy the bile ducts in the liver, leading to liver damage or eventual cirrhosis.

What are the signs and symptoms of associated with liver function?

If you or someone you know is taking Ocaliva, be sure to seek medical attention for the following signs and symptoms:

  • New or worsening tiredness
  • Diarrhea
  • Weight loss
  • Stomach pain
  • Decreased appetite
  • Nausea and vomiting
  • change in behavior or confusion
  • Anxiety or unease
  • Stomach swelling
  • Yellowing of the eyes or skin
  • Bloody stool

What is being done to warn people about these serious side effects?

The FDA is reminding healthcare providers to determine patients’ baseline liver function before starting a patient on Ocaliva.

What does the FDA recommend prescribers do?

The FDA recommends the following:

  • Patients with moderate to severe liver impairment should be started on the approved dosing schedule of 5 mg once weekly, rather than the 5 mg daily dose. 
  • Healthcare professionals should monitor patients frequently for disease progression, and reduce the dosing frequency for patients who progress to moderate or severe liver impairment.
  • All patients treated with Ocaliva should be monitored frequently for liver injury (e.g. worsened liver blood tests and adverse liver-related reactions).
  • If liver injury is suspected, discontinue Ocaliva.
  • After the patient has stabilized, weigh the benefits against the risks when deciding whether to re-initiate treatment. Educate patients about the symptoms of potential liver injury.

Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.